Clinical Characteristics and Outcomes of Type 2 Diabetes and patients Infected with COVID-19

Le résumé fourni par la source

Introduction: Diabetes and its related metabolic disorders have been reported as the leading comorbidities in patients with coronavirus disease 2019 (COVID-19). Aim: to investigate the clinical features, radiographic and laboratory tests, complications and clinical outcomes in COVID-19 patients with or without diabetes. Results: This retrospective study included 122 hospitalized patients with laboratory-confirmed COVID-19 during the period between June 2020 and January 2021. The prevalence of type 2 diabetes was 37.7% with male predominance (63.15%). More than a third of diabetic patients were smokers (37%). The mean age was more advanced in diabetic patients (65.4 years vs 61 years). All patients had comorbidity with type 2 diabetes. In COVID-19 patients with type 2 diabetes, the coexistence of hypertension (67.39% vs274.63 %), coronary heart disease (10% vs3 %), and chronic kidney diseases (10% vs 2%) was higher than in COVID-19 patients without type 2 diabetes. The frequency and degree of abnormalities in computed tomography (CT) chest scans in COVID-19 patients with type 2 diabetes were markedly increased, including ground-glass opacity and bilateral patchy shadowing (26% vs 24 %, P=0.3 ). In addition, biological inflammatory syndrome was more evident in diabetic patients. Seventeen percent of diabetic patients were hospitalized with severe acute respiratory failure (17.39% vs 15.78%). Measurements and Main Results: The coexistence of type 2 diabetes and other metabolic disorders is common in patients with COVID-19, which may potentiate the morbidity and aggravate COVID-19 progression. Optimal management of the metabolic homeostasis of glucose and lipids is the key to ensuring better clinical outcomes

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.